403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
HLS Therapeutics Inc.
(MENAFN- Baystreet) 10:17 AM EST - HLS Therapeutics Inc.: Announces its financial results for the three months ended March 31, 2026. All amounts are in thousands of United States dollars unless otherwise stated. Q1 2026 revenue was $12.9 million, Adjusted EBITDA was $3.5 million and cash from operations was $6.4 million, compared to $12.6 million, $3.8 million and $3.5 million, respectively. HLS Therapeutics Inc.
shares T are trading unchanged at $4.67.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment